VIAV Earnings

VIAV reported its earnings on 2026-04-29, showcasing a revenue of 406.80M against an estimate of 393.48M, resulting in a 3.39% surprise. The EPS was 0.27, surpassing the expected 0.24 by 12.5%. The stock experienced a 15.09% price change on the earnings day and a 18.54% change over the next five days, reflecting market reactions to the results.

Following VIAV's earnings announcement on 2026-04-29, the stock price moved by 15.09% on the day of the release. Over the subsequent five days, it saw a 18.54% change. Historically, VIAV's stock price tends to shift by an average of -4.51% in the 10 days leading up to earnings and 10.39% in the 10 days following, providing insight into potential market.

For 2026/Q4, analysts estimate VIAV's annual revenue to reach 368.77M, while the EPS is projected at 0.19. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between VIAV's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, VIAV's stock price typically moves by -4.51% in the 10 days before its earnings and 10.39% in the 10 days after. For the upcoming 2026/Q4 earnings, analysts expect an EPS of 0.19 and revenue of 368.77M.

The earnings call reveals declining financial metrics, including a 5% drop in revenue, decreased gross margins, and reduced net income, all contributing to a negative sentiment. Additionally, the lack of strategic initiatives and operational updates, coupled with management's unclear responses in the Q&A, exacerbates uncertainties. Despite a mid-sized market cap, the negative financial performance and absence of positive catalysts suggest a likely stock price decline of -2% to -8% over the next two weeks.